Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04626479
Title Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

clear cell renal cell carcinoma

Therapies

Lenvatinib + MK-1308A

Lenvatinib + MK-4280A

Lenvatinib + Pembrolizumab

Belzutifan + Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN


No variant requirements are available.